NEW YORK (Reuters Health) – The investigational GLP-1 receptor antagonist lixisenatide significantly reduces postprandial glucose excursions and HbA1c in patients with type 2 diabetes who have not been…
NEW YORK (Reuters Health) – Results of two trials indicate that verteporfin photodynamic therapy plus ranibizumab injections is no better than ranibizumab alone for treating subfoveal choroidal neovascularization…
NEW YORK (Reuters Health) – Administration of epinephrine or vasopressin to patients in cardiac arrest improves short-term survival, but has no benefit over the longer term, according to…
NEW YORK (Reuters Health) – Among patients undergoing invasive coronary angiography or PCI with the use of low-osmolar contrast media (LOCM), adverse outcomes are uncommon with no advantage…
NEW YORK (Reuters Health) – Most prostate cancers detected after more than two biopsies turn out to be clinically insignificant, according to a report from the Cleveland Clinic,…
NEW YORK (Reuters Health) – In a European study, patients at high risk of recurrent gastrointestinal stromal tumor (GIST) who received imatinib (Gleevec; Novartis) for three years after…
NEW YORK (Reuters Health) – The addition of bevacizumab (Avastin; Genentech/Roche) to the standard docetaxel and prednisone in men with progressive metastatic castration-resistant prostate cancer (mCRPC) did not…
NEW YORK (Reuters Health) – Antibiotic therapy in the first week of acute mild to moderate sinusitis is not worth it and should be avoided, conclude the authors…
NEW YORK (Reuters Health) – Goiter should be considered in the differential diagnosis of positional dyspnea, even in patients without obvious thyroid enlargement, according to a new retrospective…
NEW YORK (Reuters Health) – Women with a history of nephrolithiasis have higher fractional calcium absorption, but consuming adequate calcium reduces fractional absorption and may help prevent kidney…